Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

Ioana Agache, Claudio Rocha, Jessica Beltran, Yang Song, Margarita Posso, Ivan Solà, Pablo Alonso-Coello, Cezmi Akdis, Mubeccel Akdis, Walter Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Stefano Del Giacco, Thomas Eiwegger, Davide Firinu, James E. Gern, Eckard Hamelmann, Nicola Hanania, Mika MäkeläIrene Hernández Martín, Parameswaran Nair, Liam O’Mahony, Nikolaos G. Papadopoulos, Alberto Papi, Hae-Sim Park, Luis Pérez de Llano, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Jurgen Schwarze, Carlos Canelo-Aybar, Oscar Palomares, Marek Jutel

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalAllergy : European journal of allergy and clinical immunology
Volume75
Issue number5
Pages (from-to)1043-1057
Number of pages15
ISSN0105-4538
DOIs
Publication statusPublished - May 2020
MoE publication typeA1 Journal article-refereed

Fields of Science

  • 3121 Internal medicine
  • allergic asthma
  • benralizumab
  • cost-effectiveness
  • dupilumab
  • exacerbations
  • omalizumab
  • severe asthma
  • COST-EFFECTIVENESS ANALYSIS
  • SERUM IMMUNOGLOBULIN-E
  • TO-SEVERE ASTHMA
  • E ANTIBODY OMALIZUMAB
  • ECONOMIC EVALUATIONS
  • ADD-ON THERAPY
  • ANTIIMMUNOGLOBULIN-E THERAPY
  • SEVERE PERSISTENT ASTHMA
  • QUALITY-OF-LIFE
  • severe allergic asthma
  • EXHALED NITRIC-OXIDE

Cite this